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PHARMACOKINETIC POPULATION MODELING OF NICO-
TINE INCORPORATING CYP2A6 GENOTYPES FOLLOWING
DIFFERENT ROUTES OF ADMINISTRATION. Y. Yoon, MD,
PhD, D. Verotta, PhD, N. Benowitz, MD, University of California
San Francisco, Inje University (Korea), San Francisco, CA.
PURPOSE: We developed a comprehensive population pharma-
cokinetic (PK) model to quantify the influence of CYP2A6 genetic
polymorphisms (GP) and covariates (COV) on the PK of nicotine
following different routes of administration, and to predict individual
subjects’ PK.
METHODS: Two groups of 64 and 278 subjects received oral
(OR) and IV administration of deuterium-labeled nicotine. Genotyp-
ing of CYP2A6 (*1A, *1B, *1x2, *2, *4, *7, and *9) was carried out.
CYP2A6 GP is incorporated using indicator variables (Gi): if a
subject carries the i-th genotype Gi is 1, and it is 0 otherwise. The
influence of CYP2A6 GP on clearance, e.g., is expressed as: CL 
mi1 Gi , where m is the number of different genotypes. The
analysis yields GP and COV influence on CL, Q, V1, V2 (IV) and ka,
CL/F, Q, V1/F ((OR).
RESULTS: Body weight and age were significant COV for both
IV and OR administrations. Smoking, marital status, education, BMI
were not significant. The Asian group showed a significant decrease
in clearance (52.8%) compared to other racial groups. Race was not
significant after incorporating CYP2A6 GP. CYP2A6 *4/*4 de-
creased the clearance to 31.5 % of the wild-type clearance.
CONCLUSIONS: We elucidated the relationships between
CYP2A6 GP and COV and nicotine clearance. We are developing the
model to incorporate patch administration (PA) and developing a
Bayesian model for OR and PA.
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OATP-C(OATP01B1)*15 IS ASSOCIATED WITH STATIN-
INDUCED MYOPATHY IN HYPERCHOLESTEROLEMIC PA-
TIENTS. K. Morimoto, MS, S. Ueda, MD, N. Seki, MD, Y. Igawa,
MS, Y. Kameyama, MS, A. Shimizu, MS, T. Oishi, BS, M.
Hosokawa, PhD, K. Iesato, MD, S. Mori, MD, Y. Saito, MD, K.
Chiba, PhD, Chiba University, Nippon Kayaku Co, Ltd., The Japan
Health Sciences Foundation, Chiba, Japan.
BACKGROUND: Statins are associated with muscle complaints
ranging from myalgia to rhabdomyolysis. We studied the genetic
contribution to the risk of the statin-induced myopathy by comparing
frequencies of mutant alleles of candidate genes in case and control
groups.
METHODS: We studied ten Japanese patients with abnormal
increase in plasma creatinine kinase or severe muscle complaints, in
comparison with control patients (n26) who received statins but had
no myopathy. DNA samples were genotyped for 152 SNPs/mutations
in eight candidate genes selected from genes responsible for inherited
rhabdomyolysis and those involved in the metabolism or transport of
stains.
RESULTS: No mutations or SNPs were detected in the genes of
inherited rhabdomyolysis except for 128GA in VLCAD, of which
frequency was almost the same as that of the controls. For CYP3A4
and MRP2, one and two SNPs were detected respectively, but there
was no significant difference between the groups. However, we found
a significant association between OATP-C*15 and pravastatin- or
atorvastatin-induced myopathy (P0.01). An odds ratio of 11.3
(95%CI1.6–80.3, P0.05) was obtained when the possession of
one or more OATP-C*15 was compared. In addition, an association
between 2677GA in MDR1 and simvastatin- or atorvastatin-
incuced myopathy was also observed (P0.05).
CONCLUSIONS: The results suggest that OATP-C*15 is one of
the susceptible factors for development of myopathy in patients
taking pravastatin or atorvastatin.
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PHARMACOGENETIC VARIANTS INFLUENCE TAMOX-
IFEN’S ESTROGENIC EFFECT ON BONE DENSITY. A. T.
Nguyen, BSc, Y. Jin, MD, M. Rehman, MD, L. Li, PhD, T. C. Skaar,
PhD, V. Stearns, MD, D. F. Hayes, MD, D. A. Flockhart, MD, PhD,
Indiana University School of Medicine, John Hopkins School of
Medicine, The University of Michigan, Indianapolis, IN.
BACKGROUND: Long-term effects from tamoxifen therapy for
breast cancer include changes in bone mineral density (BMD).
METHODS: We examined the effects of menopausal status,
tamoxifen and its metabolite concentrations on BMD in 69 women
treated with 20mg of tamoxifen for one year. We tested for associ-
ations between genetic variants in CYP2D6, Estrogen Receptor 
(ER) and change in BMD, measured in the lumbar spine and hip.
Variants in CYP2D6 (*3, *4, *5, *6 and *10) and estrogen receptor
(PvuII and XbaI) were identified by RFLP assays.
RESULTS: We noted a significant decrease in lumbar BMD in
pre-menopausal women (Mean 0.069  0.057 g/cm2, p.0001).
No significant changes in post-menopausal women were found
(p.27). Pre-menopausal women with non-variant CYP2D6 geno-
types experienced greater decrease in lumbar BMD than those who
were *1/*4 or *4/*4 (p.041). The active tamoxifen metabolite
endoxifen was significantly correlated with lumbar spinal change in
this pre-menopausal group (r2  0.22, p  0.023). ER variants did
not predict these changes in BMD. In post-menopausal women who
carried the ER PvuII TT genotype there was a significant increase
in hip BMD (Mean 0.019  0.050 g/cm2, p.023).
CONCLUSION: Pre-menopausal women experienced loss in
lumbar spine BMD during tamoxifen treatment that was associated
with CYP2D6 wild-type genotype and high endoxifen concentrations.
In post-menopausal women, ER TT genotype was associated with
an increase in hip BMD.
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HERITABILITY OF DIGOXIN PHARMACOKINETICS. D. L.
Kroetz, PhD, T. Nguyen, BS, T. Giang, PharmD, L. Hodges, BS, R.
Castro, MD, E. T. Lin, PhD, C. Brett, MD, G. Swan, PhD, Univer-
sity of California San Francisco, SRI, San Francisco, CA.
BACKGROUND/AIMS: The clinical significance of genetic
variability in membrane transporters is still unclear. In this study, we
compared digoxin pharmacokinetics in monozygotic (MZ) and dizy-
gotic (DZ) twin pairs to test the hypothesis that genetic differences
contribute to interindividual variability in digoxin disposition.
Digoxin is minimally metabolized in humans and its bioavailability is
highly dependent on drug transporters.
METHODS: Each twin pair (10 MZ and 6 DZ) was administered
a 1 mg oral dose of digoxin and plasma and urine were collected over
3 days. Pharmacokinetic parameters were estimated using standard
methods. A preliminary estimate of heritability was calculated using
variability between and within the MZ twin pairs (rGC 
(VbetweenVwithin)/Vbetween).
RESULTS: Preliminary estimates indicate that 36% of the vari-
ability in oral clearance (CL/F) can be attributed to genetics (rGC 
0.359). In contrast, genetics accounts for only a minor component of
the variability in CLR (rGC  0.19). Data from DZ twin pairs will be
used to estimate the true heritability index.
CONCLUSIONS: These studies suggest that digoxin oral clear-
ance is influenced by both environmental and genetic differences
among individuals. Future studies will determine the contribution of
genetic polymorphisms in membrane transporters involved in digoxin
bioavailability on interindividual variability in digoxin pharmacoki-
netics. Supported by NIH GM61390 and the Robert Black Charitable
Foundation.
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